Skip to Main Content
CWRU Links

School of
Medicine

Neurosciences

Selected Publications

Selected Publications

Landreth Lab Publications (Since 2010)

  1. Wilkinson, B, Cramer, P, Varvel, N, Reed-Geaghan, E, Jiang, Q., Szabo, A., Herrup, K.,, Lamb, B. and Landreth, G. Ibuprofen attenuates oxidative damage through inhibition of microglial NOX2 in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Aging 33:197, e21-32, 2010. PMID: 20696495
  2. Gamboa J, Blankenship D, Niemi JP, Landreth GE, Karl M, Hilow E, Sundararajan S. Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Neuroscience170:-846-857, 2010. PMID: 20691766
  3. Reed-Geaghan, EG, Savage, JC, Hise, AG, Landreth, GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation. J Neurosci. 29:11982-92, 2009. PMID: 19776284
  4. Geldmacher, D., Fritsch, McClendon, M.J. and Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer’s disease. Arch Neurol. 68:45-50, 2010. PMID: 20837824
  5. Reed-Geaghan, E., Geaghan, Q., Cramer, P., and Landreth, G. Deletion of CD14 attenuates AD pathology by influencing the brain’s inflammatory milieu. J. Neurosci. 30:15369-15373, 2010.
  6. Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci. 31:843-50, 2011. PMID: 21248107
  7. Newbern JM, Li X, Shoemaker SE, Zhou J, Zhong J, Wu Y, Bonder D, Hollenback S, Coppola G, Specific functions for ERK/MAPK signaling during PNS development. Geschwind DH, Landreth GE, Snider WD. Neuron. 69:91-105, 2011 PMID: 21220101
  8. Lee, C.Y., Tse, W. and Landreth, G. Apoe E promotes Ab trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. 287:2032-44, 2011. PMID: 22130662
  9. Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer’s ß-amyloidosis mouse model. J. Neurosci. 31:15692-15671, 2011 PMID:22049439
  10. Cramer, PE., Cirrito, JR., Wesson, DW, Lee, C, Karlo, JC, Zinn, AE., Casali, BT, Restivo, JL, Goebel, WD ,. James, MJ, Brunden, KR, Wilson, DA and Landreth, GE. ApoE-directed Therapeutics Rapidly Clear ß-amyloid and Reverse Deficits in AD Mouse Models. Science 335:1503-1506, 2012. PMID: 22323736
  11. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-Gamma-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer’s Disease. J Neurosci. 32:10117-28, 2012. PMID: 22836247
  12. Pucilowska J, Puzerey PA, Karlo JC, Galán RF, Landreth GE. Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facial-cutaneous and related syndromes. J Neurosci. 32:8663-77, 2012. PMID:22723706
  13. Cameron, BD, Tse, W, Lamb, R, Li, X, Lamb, BT and Landreth, GE. Loss of Interleukin Receptor Associated Kinase 4 Signaling Suppresses Amyloid Pathology and Alters Microglial Phenotype in a Mouse Model of Alzheimer’s Disease. J. Neurosci. 32:15112-151123, 2012. PMID: 23100432
  14. Grommes C, Karlo JC, Caprariello A, Blankenship D, Dechant A, Landreth GE. The PPARg agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother Pharmacol. 71:929-36, 2013. PMID: 23358645
  15. Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 19:13-18. 2013. PMID 23601557
  16. Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA. Response to comments on “ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models”. Science. 2013;340:924-926, 2013. PMID: 23704556
  17. Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. Neurobiol Aging. 35:2091-5, 2014. PMID:24767949
  18. Lee, S., Xu, G., Jay, T., Bhatta, S., Kim, K.W., Jung, S., Landreth, G., Ransohoff, R and Lamb, B. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 34:12538-12546, 2014 PMID: 25209291
  19. Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE. Activation of the nuclear receptor PPARg is neuroprotective in a transgenic mouse model of Alzheimer’s disease through inhibition of inflammation. J Neuroinflammation. 12:1-7, 2015. PMID 25592770
  20. Pucilowska, J., Vithayathil, J., Tavares, E., Kelly, C., Karlo J. and Landreth, G. The 16p11.2 Deletion Mouse Model of Autism Exhibits Altered Cortical Progenitor Proliferation and Brain Cytoarchitecture Linked to the ERK MAPK Pathway. J. Neurosci. 35:3190-3200, 2015.
  21. Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer ‘s disease mouse models. J Exp Med. 212:287-295, 2015 PMID: 25732305
  22. Savage, JC, Jay, T., Goduni, E., Quigley, C., Mariani, M., Malm, T., Ransohoff, R., Lamb, BT and Landreth, GE. Nuclear receptors license phagocytosis in TREM2+ myleloid cells in mouse models of Alzheimer’s disease. J. Neurosci. 35:6532-6543, 2015.PMID 25904803
  23. Vithaytahil, J., Pucilowska, J., Goodnough,, LH., Atit, R. and GE Landreth. . Dentate gyrus development requires ERK activity to maintain progenitor population and MAPK pathway feedback regulation. J. Neurosci. 35:6836-6848, 2015 PMID: 25926459.
  24. Casali, B., Corona, A., Mariaqni, M., Karlo, J, Ghosal, K and GE Landreth. Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer’s disease. J. Neurosci. 35:9173-9181, 2015. PMID: 26085639
  25. Corona AW, Kodoma N, Casali BT, Landreth GE. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. J Neuroimmune Pharmacol. 2015 Jul 15. PMID: 26175148
  26. Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined Liver X Receptor/Peroxisome Proliferator-Activated Receptor Gamma Agonist Treatment Reduces Amyloid-ß Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J. Biol. Chem. 2015 Jul 10. pii: jbc.M115.652008. PMID: 26163517

Reviews

  1. Cameron, B. and G. Landreth. Inflammation, microglia and Alzheimer’s disease. Neurobiol. Dis. Neurobiol. Dis. 37:503-509, 2010. PMID: 19833208
  2. Mandrekar-Colucci, S. and G. Landreth. Microglia and inflammation in Alzheimer’s Disease. CNS Neurol. Disord. Drug Targets 9:157-167, 2010.
  3. Lee, C.Y. and G. Landreth. The role of microglia in amyloid clearance from the AD brain. J. Neural Trans. 117:949-960, 2010. PMID: 20552234
  4. Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets. 9:1085-1097, 2011 PMID: 21718217
  5. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid ß clearance in Alzheimer’s disease. Alzheimers Res Ther. 2013 5:33, 2013 PMID: 23849219
  6. Skerrett R, Malm T, Landreth G. Nuclear receptors in neurodegenerative diseases. Neurobiol Dis. Epub, 2014. doi: 10.1016/j.nbd.2014.05.019. PMID: 24874548.
  7. Malm TM, Jay TR, Landreth GE. The Evolving Biology of Microglia in Alzheimer’s Disease. Neurotherapeutics. 12:81-93, 2015. PMID 25404051